Recombinant Human Antibody (A2) is capable of binding to TNFA, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-TNFA mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-TNFA mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.
Figure 1 A graph showing neutralization of in vitro TNF cytotoxicity by murine A2. Control: murine IgG1 anti-lipid A mAb (8A1) with natural human TNF.
Figure 2 Graph showing that mAb A2 inhibits or neutralizes TNF produced by chimpanzee monocytes and rhTNFα.
Figure 3 Graph showing results of a cross-blocking epitope ELISA with murine A2 (mA2) antibody.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-623CL | Bovine Anti-TNF Recombinant Antibody (TAB-623CL) | Neut | Bovine IgG |
There are currently no Customer reviews or questions for PABL-349. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.